01 Set DOLUTEGRAVIR MONTHERAPY IN HIV-INFECTED NAIVE PATIENTS WITH <100.000 COPIES/ML HIV RNA LOAD, AN UPDATE OF A LITTLE COHORT IN VERONA

Stefano Nicolè

Dolutegravir is an integrase inhibitor that has a high antiviral activity and unique profile of resistance. In this report we described our experience with fourteen naïve HIV-infected patients who started dolutegravir monotherapy, rapidly achieving viral suppression. We analyzed CD4 lymphocytes and lipid profile finding a rapid immune restore and favorable metabolic impact. Despite this is an observational study of a little cohort of patients, it suggests the safety and efficacy of dolutegravir monotherapy.